Justin Stebbing

Oncology Professor in United Kingdom

Download my Covid papers (a few)

Justin trained at Trinity College, Oxford earning a first-class degree. He undertook a medicine residency at Johns Hopkins Hospital, USA, then continuing at The Royal Marsden, St Bart's Hospitals. He was from 2009-2022 Professor of Oncology at Imperial College. He has published over 650 peer-reviewed papers with an h-index of 86. The charity Action Against Cancer supports him.

He is a Fellow of the Royal College of Physicians, the Royal College of Pathologists and sits on many advisory boards. His team published in Nature Medicine the discovery of a new cancer-causing gene. Recent papers include use of biosimilars, increasing access across the developing world.

He was appointed the first NIHR oncology professor in 2011. In 2016, he was elected as co-Editor-in-Chief of Oncogene and the American Society for Clinical Investigation.

At the pandemic's start, Justin published pieces in the Lancet using artificial intelligence to find a new drug. His work on mechanistic studies and trials helped gain FDA approval for hospitalised patients with the highest mortality benefit. Justin's book ‘Witness to Covid’ describes this, with a foreword by Sid Mukherjee, a joint lecture here. In 2022 he resigned from Imperial, became Visiting Professor and a Professor at ARU, Cambridge with active research programs.

  • Education
    • Trinity College, University of Oxford
    • The Johns Hopkins Hospital, Baltimore
    • Imperial College, London
No one combines research excellence with a deep connection to his colleagues/patients like Dr. Stebbing. He led our team in leveraging our AI assets to identify drugs that could be used to treat COVID-19 and was instrumental in the breakthrough that led to clinical trials. As the first NIHR Research Translational Professor at Imperial College London, he has made great strides in identifying underlying biology and potential treatments for cancer. Justin has my highest recommendation and respect.
Joanna Shields, CEO of BenevolentAI